Celebrex

Update - September 19, 2011

A proposed Settlement has been reached in litigation across Canada dealing with the drugs Bextra and Celebrex. The Settlement, which requires the approval of the Ontario and Québec Courts, provides for the creation of a $12 million Settlement Fund from which eligible Class Members will receive compensation and from which administration costs and legal fees will be paid.

Class Members will be able to seek compensation for certain specific medical conditions, including myocardial infarction (heart attack), ischemic stroke, severe cutaneous adverse reactions and other cardiac or vascular events. Compensation may also be paid to class members for income losses, part of the costs of purchasing Bextra and/or Celebrex, and derivative claims of certain family members. A copy of the Settlement Agreement and exhibits, can be viewed by visiting the website of the Claims Administrator, Collectiva Class Action Services Inc.

Class Members may submit a claim under the proposed Settlement to the Claims Administrator now or they can exclude themselves from the proceedings by opting out. Class Members may also submit a written objection to the proposed Settlement and may attend at the Settlement Approval Hearings which are scheduled to proceed in Ontario, on November 29, 2011 at 10:00 a.m. at the Ontario Superior Court of Justice, 361 University Avenue, Toronto, and in Québec on December 2, 2011 at 9:30 a.m., at the Superior Court of Québec, 1 Notre-Dame East, Montréal.

Class Members who wish to either opt out of the proceedings or submit a written objection to the proposed Settlement must do so to the Claims Administrator by no later than November 1, 2011. Further information relating to the proposed Settlement, including the Notice, the settlement documents, Claim Packages and Opt Out Forms, is available at: www.bextracelebrexsettlement.ca, from the Claims Administrator by phone at 416-548-9874  or by writing to the following address:

Collectiva Class Action Services Inc.
285 Place d'Youville, suite 9
Montréal, Québec H2Y 2A4
Attention : Canadian Bextra/Celebrex Settlement

The law firms of McPhadden Samac Tuovi LLP, Rochon Genova LLP and Merchant Law Group LLP represent the Ontario National Classes and the law firms of Lauzon Bélanger Lespérance and Merchant Law Group LLP represent the Québec Classes.

Background

Celebrex is a selective COX-2 inhibitor, non-steroidal anti-inflammatory drug ("NSAID"). Its indications for use have included reducing inflammation and pain in the treatment of osteoarthritis, rheumatoid arthritis and primary dysmenorrhea (menstrual pain). Celebrex was approved for marketing and sale in Canada in April 1999, and is manufactured in Canada by Pfizer Canada.

Research has indicated that COX-2 inhibitors, including Celebrex, may lead to an increased risk of thrombotic cardiovascular events, such as heart attack and ischemic stroke. It is alleged that Pfizer knew of the potentially life-threatening risks associated with Celebrex, but did not adequately inform the medical community or the public.

Pfizer Canada is the Canadian operation of New York based Pfizer Inc, the world's largest pharmaceutical company. Pfizer Inc. reported revenues of 48.4 billion in 2007.

If you or someone you know has been affected by the use of Celebrex and you would like to find out more information, click here to contact us.